



Newsflash, October 2014

Connect with us soon in The Hague!

This October 23–26 we shall be at the [ESGCT](#) (European Society of Gene & Cell Therapy) annual meeting in The Hague, The Netherlands.

We would appreciate to meet you, learn about your projects and discuss how GenoSafe could be of service to your organization. Please stop by booth #9, or [contact us](#) now to schedule a specific time that works for you.



EUROPEAN SOCIETY OF GENE & CELL THERAPY
A SOCIETY DEDICATED TO THE DEVELOPMENT OF GENE THERAPY, CELL THERAPY AND GENETIC VACCINES.

Target-AMD Collaborative project

The project aims at developing a transposon-based gene therapy for the exudative form of Age-related Macular Degeneration (AMD), and translating the treatment into the first clinical trial in Europe. The consortium, led by the University of Geneva, Professor Gabriele Thumann, combines specialists in the pathology and treatment of Age-related Macular Degeneration (AMD) with key competences in the fields of genetic engineering, molecular biology, engineering, cell biology and clinician scientists. It is composed of 13 partners, SMEs, academic institutions, hospitals and a large pharmaceutical company, from 7 European countries. [More information](#)

GenoSafe is a key partner who evaluates quality of the GTMP for preclinical and clinical use, providing essential requirements to ensure the safety of the gene therapeutic TargetAMD approach.

Recently, the European Commission confirmed that the reports submitted are in accordance with the requirements of the grant agreement obtained in 2012 in the EU- Seventh Framework Programme.



New GenoSafe financial rating

The financial situation of GenoSafe has been rated “H3+” by the Banque de France. Banque de France rating reflects an evaluation of the company's ability to meet its financial commitments over a 3-year period.

This rate shows that GenoSafe has a very strong ability to meet its financial commitments. Our financial situation has been judged particularly satisfying. Our ability to resist to adverse evolution of our environment, or to the occurrence of peculiar events has been evaluated as very high.

This rating ensures that we are a financially stable company capable of providing our partners and customers with long-term project support.



[visit our website](#)

Copyright © 2014 genosafe, All rights reserved.

[unsubscribe from this list](#) [update subscription preferences](#)